| abstract |
The present disclosure discloses a chemical entity that causes cross-linking in the cornea in response to exposure to electromagnetic radiation (eg, a compound, or a pharmaceutically acceptable salt and / or hydrate and / or prodrug of the compound). It is characterized by. The present disclosure is also characterized by a composition containing the chemical entity, as well as other methods of using and producing the chemical entity. The chemical entity is useful, for example, in treating a subject (eg, a human) having a disease, disorder, or condition, where the abnormal shape of the cornea (eg, thinning of the cornea, eg, of the cornea). Bilateral thinning, eg, bilateral thinning in the center, near the center, or around the cornea; or steepening of the cornea (eg, ridge) is the pathology and / or symptoms of the disease, disorder, or condition and / Or it contributes to the progress. Non-limiting examples of such diseases, disorders, or conditions include (i) corneal ectatic disorders, (ii) visual conditions, and (iii) any of the aforementioned or any continuation of those disclosed herein. Diseases, disorders, or conditions that are onset or comorbid. More specific non-limiting examples of such diseases, disorders, or conditions include keratoconus, spherical cornea, Perusid corneal marginal degeneration, corneal ectaticism (eg, postoperative dilatation, eg, post-LASIK dilation). Disease), corneal degeneration around terien, myopia, hyperopia, astigmatism, irregular astigmatism, and LASIK. |